Syntax Bio: Series A+Develops cell therapies using proprietary Cellgorithm platform for regenerative medicineOct 4, 2026RoundOSSyntax BioCompany profile and funding historySourcesbusinesswire.comMore in BiotechAusperBio · Series CProFound Therapeutics · StrategicTransfyr · SeedBiotechUnited StatesHealthtechNorth AmericaSeries A